Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 143-149 , February 2010

International Diabetes Federation: An update of the evidence concerning the prevention of type 2 diabetes

  • R.K. Simmons

      Affiliations

    • MRC Epidemiology Unit, Cambridge, UK
    • Corresponding Author InformationCorresponding author at: MRC Epidemiology Unit, Institute of Metabolic Science, Box 285, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK. Tel.: +44 01223 330315; fax: +44 01223 330316.
    • ,
  • N. Unwin

      Affiliations

    • Institute of Health and Society, Newcastle University, Newcastle, UK
    • ,
  • S.J. Griffin

      Affiliations

    • MRC Epidemiology Unit, Cambridge, UK

Received 8 June 2009 ,Accepted 12 October 2009.

References 

  1. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet. Med. 2007;24(May (5)):451–463
  2. Simmons RK, Griffin SJ, Wareham NJ. Researching how to realize the potential of diabetes prevention. Diabet. Med. 2007;24(October (10)):1055–1057
  3. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334(February (7588)):299
  4. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368(November (9548)):1673–1679
  5. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(May (9626)):1783–1789
  6. Absetz P, Valve R, Oldenburg B, Heinonen H, Nissinen A, Fogelholm M, et al. Type 2 diabetes prevention in the “real world”: one-year results of the GOAL Implementation Trial. Diabetes Care. 2007;30(October (10)):2465–2470
  7. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001;344(May (18)):1343–1350
  8. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(March (3)):725–731
  9. Kilkkinen A, Heistaro S, Laatikainen T, Janus E, Chapman A, Absetz P, et al. Prevention of type 2 diabetes in a primary health care setting. Interim results from the Greater Green Triangle (GGT) diabetes prevention project. Diabetes Res. Clin. Pract. 2007;76(June (3)):460–462
  10. Prevent Diabetes, Live Life Well project. http://www.livelifewell.nsw.gov.au/livelifewell/diabetes/index.html.
  11. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the diabetes prevention program into the community. The DEPLOY Pilot Study. Am. J. Prev. Med. 2008;35(October (4)):357–363
  12. Lipscomb ER, Finch EA, Brizendine E, Saha CK, Hays LM, Ackermann RT. Reduced 10-year risk of coronary heart disease in patients who participated in a community-based diabetes prevention program: the DEPLOY Pilot Study. Diabetes Care. 2009;32(March (3)):394–396
  13. Rosal MC, Benjamin EM, Pekow PS, Lemon SC, von Goeler D. Opportunities and challenges for diabetes prevention at two community health centers. Diabetes Care. 2008;31(February (2)):247–254
  14. Victora CG, Habicht JP, Bryce J. Evidence-based public health: moving beyond randomized trials. Am. J. Public Health. 2004;94(March (3)):400–405
  15. Ruge T, Nystrom L, Lindahl B, Hallmans G, Norberg M, Weinehall L, et al. Recruiting high-risk individuals to a diabetes prevention program: how hard can it be?. Diabetes Care. 2007;30(July (7)):e61
  16. Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P, et al. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care. 2006;29(June (6)):1237–1241
  17. Finnish Diabetes Association, The development programme for the prevention and care of diabetes in Finland 2000–2010 (DEHKO).
  18. Schwarz PE, Lindstrom J, Kissimova-Scarbeck K, Szybinski Z, Barengo NC, Peltonen M, et al. The European perspective of type 2 diabetes prevention: diabetes in Europe—prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp. Clin. Endocrinol. Diabetes. 2008;116(March (3)):167–172
  19. NHS. www.nhs.uk/Change4Life (2009).
  20. Unal B, Critchley JA, Capewell S. Small changes in United Kingdom cardiovascular risk factors could halve coronary heart disease mortality. J. Clin. Epidemiol. 2005;58(July (7)):733–740
  21. Hill JO. Can a small-changes approach help address the obesity epidemic? A report of the joint task force of the American Society for Nutrition, Institute of Food Technologists, and International Food Information Council. Am. J. Clin. Nutr. 2009;89(February (2)):477–484
  22. Simmons RK, Harding AH, Jakes RW, Welch A, Wareham NJ, Griffin SJ. How much might achievement of diabetes prevention behaviour goals reduce the incidence of diabetes if implemented at the population level?. Diabetologia. 2006;49(May (5)):905–911
  23. Ramachandran S, French JM, Vanderpump MP, Croft P, Neary RH. Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. BMJ. 2000;320(March (7236)):676–677
  24. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008;336(May (7654)):1180–1185
  25. Goyder EC. Screening for and prevention of type 2 diabetes. BMJ. 2008;336(May (7654)):1140–1141
  26. Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, et al. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care. 2007;30(November (11)):2874–2879
  27. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care. 2007;30(October (10)):2548–2552
  28. Woolf SH. A closer look at the economic argument for disease prevention. JAMA. 2009;301(February (5)):536–538
  29. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int. J. Obes. Relat. Metab. Disord. 2000;24(September (Suppl. 3)):S6–S11
  30. Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, Williams KM, Barling RS, Butler R, et al. How much might cardiovascular risk be reduced by intensive therapy in people with screen-detected diabetes?. Diabet. Med. 2008;25:1433–1439
  31. Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease: the ADDITION study. Diabetologia. 2008;51(7):1127–1134
  32. Griffin S, Wareham NJ, Kinmoth AL, Prevost T, Barling R, Williams K. Does Intensive Treatment of Screen-detected Diabetes Improve Outcomes? One year Impact on Cardiovascular Risk Factors in the ADDITION (Cambridge) Trial. Amsterdam, Netherlands: European Association for the Study of Diabetes; 2007;
  33. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br. J. Gen. Pract. 2009;59(January (558)):43–48
  34. Eborall H, Davies R, Kinmonth AL, Griffin S, Lawton J. Patients’ experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2007;335(September (7618)):490
  35. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2007;335(September (7618)):486
  36. Goyder E, Wild S, Fischbacher C, Carlisle J, Peters J. Evaluating the impact of a national pilot screening programme for type 2 diabetes in deprived areas of England. Fam. Pract. 2008;25(October (5)):370–375
  37. DOH, Putting Prevention First, Vascular checks: risk assessment and management, London, 2008.
  38. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch. Intern. Med. 2004;164(October (19)):2147–2155
  39. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 2004;141(September (6)):421–431
  40. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008;358(June (24)):2545–2559
  41. ADVANCE . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358(June (24)):2560–2572
  42. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009;360(January (2)):129–139
  43. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359(October (15)):1577–1589
  44. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(January (1)):187–192
  45. Ilanne-Parikka P, Eriksson JG, Lindstrom J, Peltonen M, Aunola S, Hamalainen H, et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care. 2008;31(April (4)):805–807
  46. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117(March (12)):1610–1619
  47. Kohro T, Furui Y, Mitsutake N, Fujii R, Morita H, Oku S, et al. The Japanese national health screening and intervention program aimed at preventing worsening of the metabolic syndrome. Int. Heart J. 2008;49(March (2)):193–203
  48. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371(March (9614)):736–743
  49. Balagopal P, Kamalamma N, Patel TG, Misra R. A community-based diabetes prevention and management education program in a rural village in India. Diabetes Care. 2008;31(June (6)):1097–1104
  50. Seidel MC, Powell RO, Zgibor JC, Siminerio LM, Piatt GA. Translating the Diabetes Prevention Program into an urban medically underserved community: a nonrandomized prospective intervention study. Diabetes Care. 2008;31(April (4)):684–689

PII: S0168-8227(09)00428-8

doi: 10.1016/j.diabres.2009.10.003

Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 143-149 , February 2010

Article Tools